The psoriasis therapy market has become increasingly lucrative owing to the growing use of biologics. The dominance of the tumor necrosis factor (TNF)-alpha inhibitors and interleukin (IL)-12/23 inhibitor ustekinumab (Janssen’s Stelara) is being challenged by the introduction of the highly effective IL-17 inhibitors. In particular, the uptake of secukinumab (Novartis’s Cosentyx) has been remarkable in the first two years of its launch, but the agent faces competition from the newer IL-17 inhibitors—ixekizumab (Eli Lilly’s Taltz) and brodalumab (Valeant/LEO Pharma/Kyowa Hakko Kirin’s Siliq/Kyntheum/Lumicef). With the approval and launch of Janssen’s IL-23 inhibitor, guselkumab (Tremfya), another effective drug class has been introduced into this increasingly competitive market. Additionally, the landscape for the established biologics will change further with the increasing availability and use of biosimilars.

  • How do interviewed KOLs view the efficacy and safety of the IL-17 inhibitors (Cosentyx, Taltz, Siliq/Lumicef, bimekizumab), and where are/will these agents be positioned in the psoriasis treatment algorithm?
  • What will be the impact of the IL-23 inhibitors (guselkumab, Merck & Co./Almirall/Sun Pharma’s tildrakizumab, AbbVie/Boehringer Ingelheim’s risankizumab, Eli Lilly’s mirikizumab), and how will they fare in the competitive psoriasis market?
  • How is the oral agent apremilast (Celgene’s Otezla) used for psoriasis treatment, and what are the other promising emerging oral therapies?
  • How fast will the uptake of biosimilars occur in psoriasis, and which brands will experience the most erosion in patient share and sales?


Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, and Japan.

Primary research: 20 country-specific interviews with thought leaders.

Epidemiology: Number of total, diagnosed, and drug-treated prevalent cases of psoriasis; number of diagnosed prevalent cases of psoriasis by severity.

Emerging therapies: Phase II: 14drugs; Phase III/preregistration: 7 drugs; coverage of select preclinical and Phase I products.

Related Reports

Psoriasis - Geographic Focus: China - Psoriasis|China In-Depth|China

Psoriasis is an incurable chronic skin condition known to affect more than 8 million people in China. China’s psoriasis market has grown significantly over the last few years owing to the gro...

View Details

Psoriasis - Landscape & Forecast - Disease Landscape & Forecast

The psoriasis therapy market is becoming increasingly lucrative owing to the growing number of approved biologics. Although TNF-alpha inhibitors continue...

View Details

Psoriasis - Emerging Therapies - Skyrizi Launch Tracking Wave 3 (US)

In the past decade, the TNF-α inhibitors Humira (AbbVie) and Enbrel (Amgen) and the IL-12/23 inhibitor Stelara (Jan...

View Details

Psoriasis - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis Adult Psoriasis 2020 – Main Report Dashboard (US)

The adult psoriasis market has become increasingly lucrative owing to the growing use of biologics in the moderate to severe population, which cannot be adequately controlled with conventional syst...

View Details